Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial.
Nick Paul Taylor
Jul 2, 2026 8:30am
Fierce Pharma
Nature retracts provocative PD-1 time-of-day study
Jun 24, 2026 11:00am
Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial
Jun 23, 2026 7:15am
Guardant Health nabs FDA test approval for BI's new cancer drug
Jun 12, 2026 9:47am
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer
Jun 9, 2026 4:41am
ASCO: Takeda touts ‘tremendous potential’ of Innovent bispecific
Jun 2, 2026 4:30am
Fierce Pharma
Fierce Pharma
Fierce Pharma
Fierce Pharma
